28 Jul 2023
3:50 pm-5:00 pm
Innovations on the horizon!
| Panelists: Tim Fischell, Paul Teirstein, MD, … | |
| Renal Artery Denervation | |
| Role of RDN in clinical practice (debate) | |
| Renal denervation should become the primary modality to treat resistant HTN: Here is the evidence | |
| Renal denervation should be the last resort for resistant HTN (3 drugs or more)! | |
| Are we ablating the wrong target? | |
| QA | |
| Multiorgan denervation: Emerging Technology and Indications | Horst Sievert, MD |
| Q&A | |
| The Emerging Role of SuperSaturated Oxygen Therapy (SSO2) in STEMI | |
| SSO2 Therapy Overview (data and mechanism) | Greg Stone, MD |
| SSO2 Therapy Experience | … |
| Q&A |